Expand APLS Menu
APLS MENU

APLS Latest Press Releases

-- November 5, 2024 --

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results Globe Newswire 7:05 AM

-- October 26, 2024 --

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN Globe Newswire 2:00 PM

-- October 23, 2024 --

Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information Globe Newswire 5:39 PM

-- October 22, 2024 --

Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results Globe Newswire 7:00 AM

-- October 4, 2024 --

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- October 3, 2024 --

Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm Globe Newswire 12:16 PM

-- September 25, 2024 --

Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day Globe Newswire 7:00 AM

-- September 20, 2024 --

Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination Globe Newswire 5:00 AM

-- September 6, 2024 --

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- August 29, 2024 --

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences Globe Newswire 7:00 AM

-- August 8, 2024 --

Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN PRNewswire 7:29 AM
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN Globe Newswire 7:00 AM

-- August 6, 2024 --

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- August 1, 2024 --

venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies Business Wire 8:00 AM
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results Globe Newswire 7:05 AM

-- July 18, 2024 --

Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm PRNewswire 7:39 PM
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results Globe Newswire 7:00 AM

-- July 9, 2024 --

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting Globe Newswire 7:00 AM

-- June 28, 2024 --

Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Globe Newswire 6:57 AM

-- June 10, 2024 --

SYFOVRE (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA) Globe Newswire 7:00 AM